NCT06829524

HANDLE-a Real World Study on Satralizumab in NMOSD

A Real-World Practical Model of Integrated Management for Chinese Patients with Neuromyelitis Optica Spectrum Disorder (NMOSD) on Satralizumab

• Status: Not Yet Recruiting
• Phase: —
• Study type: Observational
• Enrollment: 100 (estimated)
• Sponsor: Huashan Hospital · Academic / Other
• Sex: All
• Age: 12 Years
• Healthy volunteers: Not accepted

Summary

This study is a single-center, retrospective-prospective, non-interventional cohort study to assess the clinical outcomes of Chinese NMOSD patients treated with satralizumab in a real-world patient management model by collecting follow-up data in clinical practice.

Conditions

• Neuromyelitis Optica Spectrum Disorders (NMOSD)

Interventions

Type	Name	Description
DRUG	Satralizumab	Satralizumab is the first monoclonal antibody approved for the treatment of NMOSD in China. Currently, there is still a lack of standard patient management pattern for NMOSD. While satralizumab offers the advantage of home administration, there remains a pressing need for optimized patient management.

Timeline

• Start date: 2025-03-31
• Primary completion: 2027-03-31
• Completion: 2027-06-30
• First posted: 2025-02-17
• Last updated: 2025-03-18

Locations

1 site across 1 country: China